Claudin-4 as therapeutic target in cancer

A Neesse1, H Griesmann, T M Gress

  • 1Department of Gastroenterology, Endocrinology and Metabolism, Philipps University Marburg, Baldinger Str., 35043 Marburg, Germany.

Abstract

Insights

Claudin-4, a tight junction protein, is frequently altered in epithelial cancers. Its role in tumor invasion and as a receptor for Clostridium perfringens enterotoxin (CPE) offers new diagnostic and therapeutic strategies.

Area of Science:

  • Cell biology
  • Oncology
  • Molecular medicine

Background:

  • Intercellular junctions, including adherens and tight junctions, are crucial for cellular polarity, permeability, and tissue integrity.
  • Expression analysis of cell-adhesion proteins in epithelial cancers reveals complex patterns, offering targets for evaluation.
  • Tight junctions, composed of proteins like claudins, play vital roles in maintaining epithelial barrier function.

Purpose of the Study:

  • To review the role of claudin-4 in the pathophysiology of epithelial malignancies.
  • To explore the potential of claudin-4 in prognostic, diagnostic, and therapeutic applications, with a focus on pancreatic cancer.

Main Methods:

  • Literature review focusing on claudin-4.
  • Analysis of expression data in epithelial cancers.
  • Examination of claudin-4's role as a receptor for Clostridium perfringens enterotoxin (CPE).

Main Results:

  • Claudin-4 expression is dysregulated in various epithelial malignancies and premalignant lesions.
  • Claudin-4 appears to significantly influence tumor cell invasion and metastasis.
  • Claudin-4 serves as a receptor for CPE, suggesting targeted therapeutic potential.

Conclusions:

  • Claudin-4 is a promising molecular marker for the prognosis, diagnosis, and therapy of epithelial cancers.
  • The dysregulation of claudin-4 in cancer highlights its importance in disease progression.
  • Targeting claudin-4, potentially via its interaction with CPE, presents novel therapeutic avenues.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tight Junctions01:29

Tight Junctions

Tight junctions are molecular seals between cells that prevent the leaking of fluids, ions, and other small solutes across cavities and compartments in multicellular organisms. They are mainly composed of claudin and occludin transmembrane proteins, and other proteins such as tricellulin and JAM (junctional adhesion molecule). All these proteins are 4-pass transmembrane proteins, except JAM, which is a single-pass transmembrane protein belonging to the immunoglobulin superfamily. The...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...